Generic Onyda XR Availability
Last updated on Apr 10, 2025.
Onyda XR is a brand name of clonidine, approved by the FDA in the following formulation(s):
ONYDA XR (clonidine hydrochloride - suspension, extended release;oral)
-
Manufacturer: TRIS PHARMA INC
Approval date: May 24, 2024
Strength(s): 0.1MG/ML [RLD]
Is there a generic version of Onyda XR available?
No. There is currently no therapeutically equivalent version of Onyda XR available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Onyda XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Liquid clonidine extended release composition
Patent 11,918,689
Issued: March 5, 2024
Inventor(s): Patel; Grishma
Assignee(s): TRIS PHARMA INC (Monmouth Junction, NJ)An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile. Dosage units may also provide an immediate release component.
Patent expiration dates:
- July 28, 2041✓✓
- July 28, 2041
-
Modified release formulations containing drug-ion exchange resin complexes
Patent 8,062,667
Issued: November 22, 2011
Inventor(s): Mehta; Ketan et al.
Assignee(s): Tris Pharma, Inc. (Monmouth Junction, NJ)A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
Patent expiration dates:
- March 29, 2029✓
- March 29, 2029
More about Onyda XR (clonidine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antiadrenergic agents, centrally acting
- Breastfeeding
Patient resources
Other brands
Catapres, Kapvay, Catapres-TTS, Duraclon, Nexiclon XR
Professional resources
Other brands
Catapres, Kapvay, Catapres-TTS, Duraclon, Nexiclon XR
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
